News & Events
25 March 2020 – The NZ government announced on 23rd March that as of 11:59 pm on Wednesday 25th March, the country will be put into a “lockdown”. The NZ government had introduced a 4-level Covid-19 alert system. At level 4 “lockdown”, people are instructed to stay at home, businesses are closed except for essential services (e.g. supermarkets, pharmacies, clinics) and ACS will no longer be able to operate normally.
This very rapid and strong reaction is the result of an increase in confirmed cases from 39 on Friday 20th March to 102 on Monday 23th March and more importantly, while the vast majority of cases are linked to overseas travel there now appears to be a degree of community transmission.
Consequently, we must postpone the start of new studies and need to carefully manage patients on current studies. We have been liaising with study teams to determine the best course of action for each study and patient. These measures are thought to be in place for a 4-week period. During this time ACS staff will predominantly work remotely.
The NZ Ethics committees have issued a Covid-19 Emergency Response SOP to provide further guidance.
We are optimistic that these decisive action on the back of slow, delayed start to the local outbreak will give our country a good chance to get on top of the situation quickly so that we can mirror the path of other countries that have managed Covid-19 successfully to date.
As before should you have any further questions do not hesitate to contact our Managing Director, Dr Christian Schwabe on Christian.firstname.lastname@example.org or +64 21 873 974
March 20, 2020 – We would like to assure you that ACS is monitoring the current COVID-19 situation and is putting appropriate Best Practice measures in place to minimise the risk to our trial participants and impact on studies run at ACS. New Zealand is relatively sheltered and the outbreak here so far is relatively mild.
ACS is following the New Zealand Ministry of Health and District Health Board guidelines on risk assessment:
All travellers coming into New Zealand must self-isolate for 14 days. You cannot attend ACS until self-isolation is complete. (For those arriving prior to 16Mar20 and 19Mar20 mandatory self-isolation): If you have arrived in New Zealand from any country, you should self-isolate for 14 days from your date of departure. You cannot attend ACS until self-isolation is complete.
In addition, you will not be able to attend ACS if you have:
– a fever OR
– been in close contact with someone with a confirmed case of COVID-19 infection in the last 14 days. Please also contact Healthline on 0800 358 5453 if not already done so.
If you are participating in a trial or are scheduled to screen for a study, please also notify the study team on 0800 STUDIES or the study email address.
ACS will continue to review and update our processes and guidelines as the situation evolves. Should you have any further questions do not hesitate to contact either 0800 STUDIES or email@example.com
ACS Director and Principal Investigator, Professor Ed Gane, named as one of five University of Auckland researchers most highly cited!
Nov 20, 2019 – The highly anticipated Web of Science Group 2019 list identifies scientists and social scientists who produced multiple papers ranking in the top one percent by citations for their field and year of publication, demonstrating significant research influence among their peers. This list includes ACS Director and Principal Investigator, Professor Ed Gane of the School of Medicine at The University of Auckland.
Read more Here
ACS stand out among IQVIA preferred clinical trial sitesMay 24, 2018 – Auckland Clinical Studies has been recognized for superior performance and quality in clinical research in 2017. After being selected by IQVIA In November 2016 as their first preferred partner clinical trial site globally, ACS is tremendously pleased how well the collaboration is progressing. Mary Ellis-Pegler, ACS Operations Manager, commented “In 2017, the team worked extremely hard on a number of very big projects with IQVIA. It is really nice to see the effort and quality being recognized by IQVIA, a world leading CROs and recently selected as one of the 2018 FORTUNE “World’s Most Admired Companies. We especially enjoy the collaborative spirit of the partnership and look forward to many more successful projects in the future”
Top row, L-R: Ben Oldfield (ACS Principal Pharmacist), Amalini Jesuthasan (ACS Laboratory Manager), Janet Patterson (ACS Quality Manager)
Second row, L-R: Tara Shadbolt (ACS Charge Nurse), Katie Lim (ACS Quality/Regulatory Associate), Mary Ellis-Pegler (ACS Operations Manager)
Third row, L-R: Prof Ed Gane, Assoc. Prof Wai-Kay Seto, Wen-Jing Zhou (Manager, HKU Clinical Trials Centre), Dr Li Yang (Oncologist, HKU-Shenzhen Hospital), Dr Christian Schwabe (ACS Managing Director)
University of Hong Kong-Shenzhen Hospital delegation visiting ACS
March 7, 2018 – A delegation from the Clinical Trials Centre at The University of Hong Kong-Shenzhen Hospital, recently spent 3 days at Auckland Clinical Studies. Shenzhen Hospital is a large, modern public hospital in Futian District, Shenzhen, Guangdong, China and is one of the two teaching hospitals of the University of Hong Kong. The clinical trials centre is set to become a major player in early phase clinical research in China and came to Auckland to gain further insight into best practice phase 1 research recognizing ACS’ world-leading status in this setting.
“ACS has an enviable global reputation not only based on their contribution to finding very effective new treatments for chronic hepatitis C, but also as a result of innovative studies in many other therapeutic indications including oncology rare diseases” – Associate Prof Wai-Kay Seto, Clinical Associate Professor at the Department of Medicine,The University of Hong Kong.
“This meeting provides a fantastic opportunity to build a strong collaboration between our two units, which should be mutually beneficial. In future, we could provide a combined force for securing ongoing early phase studies”. – Prof Gane, Professor of Medicine at the University of Auckland, New Zealand, Chief Hepatologist, Transplant Physician and Deputy Director of the New Zealand Liver Transplant Unit at Auckland City Hospital and Clinical Director of Auckland Clinical Studies
Symposium to celebrate 10yrs of ACS
ACS was established to provide a location for Auckland City Hospital clinical investigators for Phase I and Phase II studies. Over the last 10 years, ACS has grown to 35 beds and 80 staff (including 6 research physicians, 4 Pharmacists, 9 study coordinators, 40 nurses, 18 laboratory staff, transcriptionists and admin staff).
Close to 200 studies have now been performed across most ACH specialties including dermatology, gastroenterology, haematology, hepatology, infectious diseases, nephrology, neurlogy, paediatrics, oncology and respiratory medicine.
The symposium on 12th October 2017 at the Marion Davis Libraray at ACH was to celebrate the last 10yrs with Notable invited speakers including principal investigators from Auckland City Hospital and leaders from pharmaceutical industry.
ACS turns 10!
28 April 2017 – Auckland Clinical Studies (ACS) proudly celebrated 10 years as an early phase clinical pharmacology unit in Auckland, New Zealand. Providing outstanding quality service in clinical research, ACS has successfully completed >150 studies to date.
Highlights of achievements over the last 10 years for ACS and its staff included:
- Been an integral part of an international search for a cure for hepatitis C and treated 1200 patients in NZ most of whom are cured of their disease now
- Related to above, ACS Director Professor Ed Gane was awarded MNZM in 2011 New Year’s Honours for services to Medicine, the Health Research Council 2014 Liley Award for his work in hepatitis C and the 2017 NZ Innovator of the Year Award
- Selected as Global Prime Site for Quintiles, the World’s largest Clinical Research Organisation
Congratulations ACS, and to many more successes to come!
Congratulations to Professor Ed Gane, the 2017 New Zealand Innovator of the year
Professor Ed Gane’s outstanding contributions to the development of a simple and potent cure for chronic Hepatitis C were recently recognized when he was named the 2017 New Zealand Innovator of the year.
The New Zealander of the Year Awards celebrate people who use their passion for New Zealand to make our country a better place. These awards are a wonderful opportunity to honor extraordinary Kiwis whose selflessness, creativity and vision make us proud to call New Zealand home.
Auckland Clinical Studies is very proud of Ed’s fantastic achievement and grateful to have been able to help Ed’s search for a better and more effective Hepatitis C treatment. We want to join Ed in thanking the 1000+ patients who participated in studies here, and whose contribution helped find a cure for more than a million patients around the world so far.
Eradication of the Hepatitis C virus infection in New Zealand and around the world is now really a possibility. This will require identifying the approximately 20 000 New Zealanders that harbour the virus without knowing it. Knowing Ed, we are confident he will find a way to tackle this challenge too.
For further information, visit http://nzawards.org.nz/awards/new-zealand-innovator-year/2017/
Auckland Clinical Studies and QuintilesIMS Sign
Early Clinical Development Prime Site Alliance Agreement
ACS joins Christchurch Clinical Studies Trust as the first two ECD QuintilesIMS Prime Sites
Auckland, New Zealand – November 10, 2016 – Auckland Clinical Studies (ACS) this week became one of the first two early clinical development (ECD) centers to join the QuintilesIMS Prime Site program, a global network of highly qualified sites collaborating with QuintilesIMS to improve the speed, efficiency and quality of clinical research across all phases of development.
Through the agreement signed this week, ACS and QuintilesIMS will strategically collaborate to raise the efficiency and volume of ECD research conducted in New Zealand on behalf of biopharmaceutical and medical device companies. ACS has worked with QuintilesIMS for 10 years; the Prime Site alliance will take that collaboration to the next level.
“The addition of Auckland Clinical Studies as one of our first ECD Prime Sites is testament to the quality of medical research in New Zealand,” said Vice President Ashish Jain, Global Early Clinical Development, QuintilesIMS. “This alliance further strengthens our ability to meet our customers’ early clinical development needs in Asia Pacific across a wide range of therapeutic areas.”
The ultimate goal for both QuintilesIMS and ACS is to help companies develop better treatments faster and give more patients the option of participating in clinical research. ACS joins Christchurch Clinical Studies Trust (CCST) as the Prime Site program’s first two ECD centers. CCST also signed an alliance agreement with QuintilesIMS earlier this week.
ACS has access to the large patient/volunteer population in Auckland, New Zealand’s largest city, with 2 million people. It is located directly opposite Auckland’s leading tertiary referral hospital, Auckland City Hospital (ACH), and has access to a full range of medical specialties and LabPLUS, ACH’s premier medical laboratory. ACS also has access to many researchers from the Auckland School of Medicine and Auckland’s major tertiary hospitals who are keen to take part Phase I and II studies.
Supported by a robust and world leading ethical and regulatory framework in New Zealand, ACS is a world leader in early clinical development, particularly for studies requiring novel or complex designs.
QuintilesIMS is a leading integrated information and technology-enabled healthcare service provider worldwide, dedicated to helping its clients improve their clinical, scientific and commercial results. QuintilesIMS’s approximately 50,000 employees conduct operations in more than 100 countries.
Companies seeking to improve real-world patient outcomes through treatment innovations, care provision and access can leverage QuintilesIMS’s broad range of healthcare information, technology and service solutions to drive new insights and approaches.
These insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders in the development and approval of new therapies, and to identify unmet treatment needs and understand the safety, effectiveness and value of pharmaceutical products in improving overall health outcomes.
Professor Ed Gane receiving the 2014 Health Research Council of New Zealand’s distinguished Liley Medal
We would like to congratulate our colleague Professor Ed Gane for receiving the 2014 Health Research Council of New Zealand’s distinguished Liley Medal for demonstrating a safer, more effective treatment for people with hepatitis C virus. The Liley Medal recognises Professor Gane’s outstanding contribution to the health and medical sciences in the field of clinical hepatology. Professor Gane was the lead author on two very highly cited papers in the prestigious medical journal, New England Journal of Medicine, which showed that people could be cured of the hepatitis C virus in just 12 weeks using an antiviral treatment called sofosbuvir.
A significant proportion of the research leading to this prestigious award was conducted at Auckland Clinical Studies. We would also like to use this opportunity to thank the more than 500 patients who have participated in Hepatitis C studies at ACS over the last few years and have made this outstanding progress in the treatment of this devastating disease possible.